Industry Guide
From protecting your research to hiring your first scientist, biotech companies face legal challenges unique to the industry. This guide breaks down what you need to know.
IP is often the most valuable asset a biotech company holds. Unlike physical products, research findings, novel compounds, and proprietary processes can be copied unless legally protected. Getting this right early is critical.
IP Assignment Agreements
Every founder, employee, and contractor should sign an IP assignment agreement before they start work. This ensures anything created using company resources belongs to the company, not the individual.
Trade Secrets vs. Patents
Processes that are difficult to reverse-engineer are often better protected as trade secrets, which have no expiration date. Patents require public disclosure and expire after 20 years.
University Tech Transfer
If your technology originated at a university, you need a formal license agreement from the technology transfer office. Do not assume the IP is yours just because you created it as a student or postdoc.
Watch Out: Prior Disclosure
Publishing research before filing a patent application can destroy your patent rights in most countries. Always file a provisional patent application before any public disclosure.
Recommended Templates:
Biotech companies share sensitive research data constantly - with potential partners, contract research organizations, academic collaborators, and investors. A well-drafted NDA is your first line of defense before any confidential conversation begins.
Use a Mutual NDA for Two-Way Exchanges
When both parties are sharing confidential information, use a mutual NDA. Common in partnership discussions, joint development conversations, and co-research arrangements.
Use a One-Way NDA for Disclosures to Third Parties
When you are the only one sharing confidential information, such as in vendor evaluations or investor presentations, a one-way NDA provides targeted protection.
Biotech-Specific NDA Clauses to Include
Make sure your NDA explicitly covers: compound structures, assay data, cell lines, genomic data, clinical trial protocols, and regulatory submissions.
Material Transfer Agreements (MTAs)
When physical research materials are shared, an NDA alone is not sufficient. An MTA governs the use, storage, and return or destruction of the materials themselves.
Early-stage biotech companies frequently use contractors and scientific advisory board members before hiring full-time employees. These relationships carry specific legal risks if not properly documented.
IP Assignment is Non-Negotiable
Every contractor must sign an IP assignment clause. If a contractor develops a key assay on your project with no signed agreement, they may own the IP.
Scientific Advisory Boards
SAB members should sign advisor agreements specifying compensation (usually equity), time commitment, confidentiality obligations, and IP assignment.
Misclassification Risk
Contractors who work exclusively for you and follow your direction may legally be employees under IRS rules. Misclassification carries significant tax and legal penalties.
Consulting Professors
When working with university professors, check their institution's conflict-of-interest and IP policies. Many universities claim rights to consulting work done using institutional resources.
Hiring in biotech involves additional considerations beyond standard employment law. Candidates from academia or large pharma companies often have existing IP obligations.
Check for Existing IP Encumbrances
Before making an offer, ask candidates about any IP assignments, non-competes, or confidentiality agreements with prior employers.
Include an IP Assignment in Every Offer Letter
Your offer letter should state clearly that all work-related inventions belong to the company. State laws vary on what can be assigned.
Non-Compete Enforceability Varies by State
California, Minnesota, and several other states do not enforce employee non-competes. If you are in a state that does, they must be narrowly scoped.
Equity and Vesting Schedules
Biotech employees frequently accept lower salaries for equity. Standard vesting is four years with a one-year cliff. Document this clearly in the offer letter.
Choosing the right corporate structure early affects taxes, fundraising options, IP ownership, and liability. Most investor-backed biotech companies incorporate as C-corporations in Delaware.
Delaware C-Corp for VC-Backed Companies
If you plan to raise venture capital, investors almost universally require a Delaware C-corporation. Delaware law is well-developed and most VC term sheets assume this structure.
LLC for Early Flexibility
A single-member or multi-member LLC works well for the earliest stage, especially for bootstrap or grant-funded research. It can be converted to a C-corp later.
Academic Spin-Out Considerations
University spin-outs must typically license IP from the institution and may have the university take equity. The structure of this arrangement affects how future investors view the cap table.
Joint Ventures with Research Institutions
Biotech often involves formal collaborations with hospitals or larger pharma. These are governed by joint venture or sponsored research agreements that specify IP rights and royalty sharing.
Contract Research Organizations, manufacturers, reagent suppliers, and lab service providers are the backbone of biotech operations. Each requires a proper agreement protecting your data, IP, and timelines.
CRO Agreements
Address: scope of work, timelines, data ownership (you should own all raw data), IP assignment, confidentiality, right to audit, and what happens if results are challenged in a regulatory context.
Manufacturing and Scale-Up Agreements
Cover quality standards, batch record access, inspection rights, IP in the manufacturing process, and liability for batch failures.
Reagent and Material Supply
Review the use rights in any supplier agreement before entering a commercial program that depends on that reagent.
Service Level Agreements
For any vendor critical to your pipeline or regulatory submission timeline, negotiate an SLA with clear deliverables, timelines, and remedies for delay.
Biotech companies working with patient samples, genomic data, or clinical data face strict regulatory obligations under HIPAA in the United States and GDPR in Europe.
HIPAA Applies to Business Associates
Even if you are not a covered entity, if you receive protected health information from one, you are a business associate and must sign a BAA.
De-Identified Data Has Fewer Restrictions
Properly de-identified data under the HIPAA Safe Harbor method is not subject to HIPAA, significantly reducing compliance burden.
Genomic Data is a Special Category
Genomic data is treated as highly sensitive under GDPR and many US state laws. It cannot be truly de-identified since it is inherently unique.
Patient Consent Documentation
For any research involving human subjects, informed consent must be documented and stored. IRB approval and consent forms are legally required.
Regulatory strategy shapes nearly every other legal decision in biotech. The pathway you choose - IND, 510(k), PMA, or BLA - determines your timeline and data requirements.
IND Applications and Pre-IND Meetings
Before initiating clinical trials in the US, most therapeutics require an IND application. Request a pre-IND meeting with the FDA early. Feedback shapes your development program.
Quality Agreements with Contract Manufacturers
FDA requires that sponsors maintain quality agreements with any contract manufacturer producing clinical or commercial materials.
Clinical Trial Agreements
When running multi-site clinical trials, each site requires a CTA with the sponsoring company covering indemnification, data ownership, publication rights, and site payments.
Orphan Drug and Breakthrough Designations
Certain FDA designations affect exclusivity rights and negotiating position. These should be reflected in any licensing or collaboration agreement.
⚠ Legal Disclaimer
This guide is for general informational purposes only and does not constitute legal advice. Biotech regulations vary by jurisdiction and change frequently. Always consult a licensed attorney specializing in life sciences for guidance specific to your company and situation.